WAVE Life Sciences (NASDAQ:WVE) Releases Earnings Results, Beats Expectations By $0.21 EPS

WAVE Life Sciences (NASDAQ:WVE) issued its earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.21, FiscalAI reports. The business had revenue of $38.25 million during the quarter, compared to analysts’ expectations of $8.45 million. WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%.

Here are the key takeaways from WAVE Life Sciences’ conference call:

• Wave is accelerating WVE-007 (INHBE GalNAc?siRNA) into the phase II?A multi?dose trial this quarter after phase I showed durable Activin E suppression and a placebo?adjusted 14.3% visceral fat reduction with lean mass preservation, supporting once? or twice?year dosing and combination/maintenance strategies.
• RNA?editing candidate WVE?006 for AATD has produced therapeutically relevant restoration of AAT (including >20 µM during acute phase responses), will present expanded data at ATS, and management expects regulatory feedback on a possible accelerated approval pathway in mid?2026.
• The pipeline is broadening — WVE?008 (PNPLA3 I148M) is being advanced toward first?in?human studies with a planned CTA in 2026 to address an estimated 9 million homozygous carriers, and Wave is progressing bifunctional and extrahepatic programs.
• Financially, revenue rose to $38.2M and net loss narrowed to $26.1M in Q1; Wave ended the quarter with $544.6M in cash, which management says funds operations into Q3 2028.
• Clinical and regulatory uncertainty and competition remain material risks — R&D and G&A spending increased quarter?over?quarter, key programs are still early stage (dose?finding and durability questions remain), and other modalities (DNA editors, combo regimens) represent competitive pressures.

WAVE Life Sciences Stock Performance

WAVE Life Sciences stock traded down $0.05 during midday trading on Thursday, reaching $7.01. The company’s stock had a trading volume of 394,181 shares, compared to its average volume of 4,274,593. WAVE Life Sciences has a fifty-two week low of $5.02 and a fifty-two week high of $21.73. The stock’s 50 day simple moving average is $10.16 and its 200 day simple moving average is $11.24. The firm has a market capitalization of $1.32 billion, a PE ratio of -5.76 and a beta of -1.32.

Insider Transactions at WAVE Life Sciences

In other WAVE Life Sciences news, insider Chandra Vargeese sold 3,228 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $43,416.60. Following the transaction, the insider directly owned 408,246 shares of the company’s stock, valued at $5,490,908.70. This represents a 0.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Paul Bolno sold 10,480 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $140,956.00. Following the sale, the chief executive officer directly owned 275,520 shares in the company, valued at approximately $3,705,744. This represents a 3.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 52,373 shares of company stock worth $757,527. Corporate insiders own 23.98% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG grew its stake in WAVE Life Sciences by 1.5% during the 4th quarter. Deutsche Bank AG now owns 95,706 shares of the company’s stock worth $1,627,000 after buying an additional 1,441 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of WAVE Life Sciences by 645.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock valued at $38,000 after buying an additional 1,942 shares during the period. Nebula Research & Development LLC lifted its holdings in shares of WAVE Life Sciences by 8.7% during the second quarter. Nebula Research & Development LLC now owns 34,342 shares of the company’s stock valued at $223,000 after purchasing an additional 2,748 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of WAVE Life Sciences by 7.7% during the third quarter. Envestnet Asset Management Inc. now owns 39,847 shares of the company’s stock valued at $292,000 after purchasing an additional 2,866 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in WAVE Life Sciences by 44.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,658 shares of the company’s stock worth $76,000 after acquiring an additional 3,609 shares in the last quarter. 89.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on WVE shares. Canaccord Genuity Group upped their price target on WAVE Life Sciences from $43.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Monday, April 20th. Mizuho increased their target price on WAVE Life Sciences from $22.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, March 25th. Wells Fargo & Company reduced their target price on WAVE Life Sciences from $27.00 to $13.00 and set an “overweight” rating for the company in a research note on Friday, March 27th. Finally, Truist Financial started coverage on WAVE Life Sciences in a research note on Wednesday. They set a “buy” rating and a $15.00 target price for the company. Fourteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $28.44.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.